2024
TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3
Perales O, Jilaveanu L, Adeniran A, Su D, Hurwitz M, Braun D, Kluger H, Schoenfeld D. TIGIT expression in renal cell carcinoma infiltrating T cells is variable and inversely correlated with PD-1 and LAG3. Cancer Immunology, Immunotherapy 2024, 73: 192. PMID: 39105820, PMCID: PMC11303630, DOI: 10.1007/s00262-024-03773-8.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaRenal cell carcinoma tumorsT cellsTIGIT expressionCheckpoint inhibitorsPD-1Likelihood of response to therapyTumor-infiltrating T cellsCD3+ T cellsRenal cell carcinoma metastasisTreatment of renal cell carcinomaImmune checkpoint inhibitorsInfiltrating T cellsPurposeImmune checkpoint inhibitorsResponse to therapyT cell immunoglobulinCD3+ levelsMetastatic RCC specimensAdjacent normal renal tissuesNormal renal tissuesQuantitative immunofluorescence analysisCell carcinomaResistant diseasePotential therapeutic targetTissue microarray
2023
Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases
Schoenfeld D, Moutafi M, Martinez S, Djureinovic D, Merkin R, Adeniran A, Braun D, Signoretti S, Choueiri T, Parisi F, Hurwitz M, Rimm D, Wei W, Jilaveanu L, Kluger H. Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases. Journal For ImmunoTherapy Of Cancer 2023, 11: e007240. PMID: 37586773, PMCID: PMC10432651, DOI: 10.1136/jitc-2023-007240.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsCarcinoma, Renal CellHepatitis A Virus Cellular Receptor 2HumansImmune System DiseasesKidney NeoplasmsMedical OncologyTumor MicroenvironmentConceptsRenal cell carcinomaBrain metastasesPrimary tumorTumor microenvironmentDigital spatial profilingCell carcinomaActivation protein expressionInflammatory macrophage markersRCC brain metastasesInnate immune activatorsNormal kidney samplesProgressive stagesExtracranial metastasesTim-3Immune checkpointsImmune dysfunctionImmune activationRCC metastasisLonger survivalImmune activatorsMacrophage markersTreatment responseSeparate cohortTissue microarrayMetastatic samples
2016
Racial disparities in renal cell carcinoma: a single‐payer healthcare experience
Mafolasire A, Yao X, Nawaf C, Suarez‐Sarmiento A, Chow W, Zhao W, Corley D, Hofmann JN, Purdue M, Adeniran AJ, Shuch B. Racial disparities in renal cell carcinoma: a single‐payer healthcare experience. Cancer Medicine 2016, 5: 2101-2108. PMID: 27228559, PMCID: PMC4884637, DOI: 10.1002/cam4.755.Peer-Reviewed Original ResearchConceptsDisease-specific survivalRenal cell carcinomaBlack patientsIndependent predictorsSurgical treatmentWhite patientsCell carcinomaRacial disparitiesKaiser Permanente Northern California systemWorse disease-specific survivalCox proportion hazard modelAdvanced American Joint CommitteePapillary renal cell carcinomaKaplan-Meier methodProportion hazard modelAmerican Joint CommitteeLarger tumor sizeCase-control studyHealthcare systemSingle-payer healthcare systemSingle healthcare systemSignificant racial disparitiesOverall survivalPatient demographicsDifferent comorbiditiesGenomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma
Bi M, Zhao S, Said JW, Merino MJ, Adeniran AJ, Xie Z, Nawaf CB, Choi J, Belldegrun AS, Pantuck AJ, Kluger HM, Bilgüvar K, Lifton RP, Shuch B. Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: 2170-2175. PMID: 26864202, PMCID: PMC4776463, DOI: 10.1073/pnas.1525735113.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Renal CellCell DedifferentiationDNA Mismatch RepairDNA-Binding ProteinsExomeFemaleGenes, p53HumansKidney NeoplasmsLoss of HeterozygosityMaleMiddle AgedMutationNuclear ProteinsOncogenesPolymorphism, Single NucleotidePrognosisTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseConceptsClear cell renal cell carcinomaCell renal cell carcinomaRenal cell carcinomaSarcomatoid elementsCarcinomatous elementsCell carcinomaSomatic single nucleotide variantsVon Hippel-Lindau tumor suppressorPoor-prognosis cancerTreatment of patientsTumor protein p53 (TP53) mutationsMismatch repair deficiencyRich interaction domain 1ASarcomatoid featuresPoor prognosisUnknown pathogenesisPolybromo-1TP53 mutationsP53 mutationsSarcomatoid transformationPan-cancer genesExome sequencingTumorsRepair deficiencyProtein 1
2010
Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases
Feifer A, Savage C, Rayala H, Lowrance W, Gotto G, Sprenkle P, Gupta A, Taylor J, Bernstein M, Adeniran A, Tickoo SK, Reuter VE, Russo P. Prognostic Impact of Muscular Venous Branch Invasion in Localized Renal Cell Carcinoma Cases. Journal Of Urology 2010, 185: 37-42. PMID: 21074196, PMCID: PMC3437930, DOI: 10.1016/j.juro.2010.08.084.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Renal CellHumansKidney NeoplasmsMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessPrognosisRenal VeinsRetrospective StudiesVascular NeoplasmsConceptsRenal vein invasionRenal cell carcinoma casesVein invasionInvasion groupCarcinoma casesCareful pathological assessmentMultivariate Cox modelOverall survival rateAmerican Joint CommitteeCancer (AJCC) staging systemRisk of recurrencePrognostic equivalencePrognostic impactTumor characteristicsAdverse prognosisRadical nephrectomyRecurrence rateVascular invasionStaging systemNephrectomy specimenPathological assessmentCox modelPatientsJoint CommitteeSurvival rate